Market cap
$2.4b
End-of-day close multiplied by current shares on issue.
Headline NPAT declines just 3.8% on a 30.2% tax credit, but underlying profit is flat and pre-lease cash flow sits well below the historical range.
Revenue context before the current result.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Statutory profit after tax across covered periods.
Market context
A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.
The latest close and share count context for the market price.
Market cap
$2.4b
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.17
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
44.6x
Enterprise value compared with recent EBITDA.
P/FCF
12.57x
Market cap compared with recent free cash flow.
P/B
0.58x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Key metrics
HY24 vs HY23
Revenue
$323m
+17.8% ↑ vs $274.2m
EBITDA
$146.3m
— vs —
Net profit after tax
$186.7m
-3.8% ↓ vs $194m
Net cash inflow from operating activities
$337.9m
+38.7% ↑ vs $243.7m
Interim dividend per share
0.0c
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
Profit before tax
$143.4m
-34.0% ↓ vs $217.3m
Cash and cash equivalents
$33.3m
+28.7% ↑ vs $25.9m
Total assets
$13.1b
+8.7% ↑ vs $12b
What changed
The board responded by zeroing the interim dividend (versus 8.8 cents per share in HY23), the most concrete capital allocation signal in the release.
Top-line momentum was strong: revenue grew 17.8% to $323.0m, above the historical baseline mean of 12.3%. Operating EBITDA rose 7.8% to $146.3m and underlying profit was effectively flat at $139.2m (+0.3%). Statutory PBT fell 34.0% to $143.4m, but NPAT dropped only 3.8% to $186.7m because the effective tax rate swung from -10.7% to +30.2% — a tax credit that masks the operating decline.
Net debt fell to $2.47bn (gearing 33.6%) while capex more than doubled (+130.7%) to $442.8m.
What matters
The cleaner read is PBT growth of -34.0% or underlying profit growth of +0.3%, not the -3.8% NPAT decline. The 30.2 percentage point gap between PBT and NPAT growth is entirely tax-driven and will not repeat. Underlying earnings power has flatlined despite strong revenue growth because, per management, lower new sales at sites under development offset operating EBITDA gains.
Free cash flow continues to lag development spend. OCF rose 38.7% to $337.9m, but capex of $442.8m (137.1% of revenue) pushed pre-lease FCF to -$158.4m. The $138.5m improvement versus HY23 is real, but the cash gap to the historical mean explains why the board prioritised balance-sheet repair over a distribution.
Australia segment result collapsed. Australian revenue grew to $52.5m (16.3% of group versus 12.2% prior), but the segment result fell from $65.3m to $12.3m — a $53m swing not explained in the supplied release excerpts. New Zealand result also slipped modestly from $128.7m to $127.0m despite stronger revenue.
Expectations
Management cites "lower new sales in sites under development" as the offset to operating EBITDA growth, which means the second-half read depends on settlement activity at unfinished villages — a variable the release does not quantify. The dividend pause matters because it removes the prior signal of NPAT-based payout discipline (HY23 payout ratio was 22.7%) and ties any future distribution to a cash-flow recovery the release does not yet show.
Quality of result
Underlying profit being essentially flat indicates operating gains are being absorbed by lower development-stage sales activity rather than translating to bottom-line growth.
The NPAT line is balance-sheet-assisted via a tax credit; the +30.2% effective rate is well outside the supplied historical baseline mean of -23.0%. ROE fell from 5.3% to 3.8% on a much larger equity base ($4.86bn versus $3.63bn), so the increase in retained capital is not yet earning its keep. With capex running at 137.1% of revenue, pre-lease FCF at -$158.4m, and the dividend suspended, the gap between accounting profit and distributable cash is the central durability question. The 231.0% OCF-to-EBITDA conversion looks flattering but reflects resident deposit inflows rather than free cash, and does not survive contact with development capex.
Unresolved
This briefing cannot assess management's medium-term development pipeline, scheduled village completions, or sector demand dynamics because the supplied release excerpts do not include that information.
Chat
Ask follow-up questions about Ryman Healthcare's HY24 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load segment breakdown.
Open to load analytical metrics.
Open to load key metrics.
Ryman Healthcare Limited - Announcement Numbers and Financial Statements - 30 September 2023
HY24 / financial reportRyman Healthcare Limited - Media Release and Key Statistics - 30 September 2023
HY24 / media releaseRyman Healthcare Limited - Result Presentation - 30 September 2023
HY24 / results presentationRyman Healthcare Limited - Announcement Numbers and financial statements - 30 September 2022
HY23 / financial reportRyman Healthcare Limited - Media Release and Key Statistics - 30 September 2022
HY23 / media releaseRyman Healthcare Limited - Half Year Result Webcast - 30 September 2023
HY24 / commentaryRelated insights
Cross-company views selected from the metrics in this briefing.
Earnings quality and statutory distortions
PBT and NPAT growth diverged by 30.2pp, with a distortion flag in the result.
Leverage and balance-sheet risk
Net debt / EBITDA is 16.86x for this result.
Cash conversion quality
This result converted 231.0% of EBITDA to operating cash flow.
Revenue growth context
Revenue growth was 17.8% for this reporting period.
Get the next Ryman Healthcare briefing and related NZX reporting-season updates by email.